Integrated Diagnostics (IDHC) Q3 2025 TU earnings summary

Executive summary

• Achieved 41% year-over-year revenue growth to EGP 5.8 billion in 9M 2025, driven by a 10% increase in test volumes and a 28% rise in average revenue per test, with significant margin improvements at all levels.

• Delivered broad-based growth across Egypt, Jordan, Nigeria, and Saudi Arabia, supported by network expansion, operational optimization, and service diversification.

• Egypt remains the main revenue engine, contributing 84% of total revenues.

• Normalized net profit surged 119% year-over-year to EGP 1,005 million, with a margin of 17% versus 11% in 9M 2024; net profit grew 33% to EGP 964 million.

• Expanded branch network by 105 locations, reaching 713 branches across five countries.

Financial highlights

• Revenue grew 41% year-on-year for the first nine months of 2025, with test volumes up 10% and average revenue per test up 28%.

• Gross profit rose 60% year-over-year to EGP 2.5 billion, with margin improving to 43% from 38%.

• EBITDA increased 63% to EGP 2.0 billion, with margin up to 35% from 30% last year.

• Net profit reached EGP 964 million, up 33% year-on-year; adjusted net profit margin expanded to 17% from 11%.

• Cash reserves stood at EGP 1.8 billion, with a net cash balance of EGP 271 million as of September 30, 2025.

Outlook and guidance

• Full-year 2025 revenue growth expected to exceed 35%, with management targeting 30% year-over-year consolidated growth.

• EBITDA margin guidance remains above 30%, supported by cost discipline and improved Nigerian operations.

• Price increases in Egypt planned for 2026, with details pending.

• Saudi operations expected to reach EBITDA break-even by end of 2026, with three additional branches planned by year-end.

• Digitalization and cost management expected to support margin improvements.